These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34599756)

  • 61. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoadjuvant therapy sequencing.
    Lee AJ; Simoneau E; Chiang YJ; Lee JE; Kim MP; Aloia TA; Vauthey JN; Katz MH; Tzeng CD
    HPB (Oxford); 2019 Sep; 21(9):1203-1210. PubMed ID: 30799277
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.
    Truty MJ; Kendrick ML; Nagorney DM; Smoot RL; Cleary SP; Graham RP; Goenka AH; Hallemeier CL; Haddock MG; Harmsen WS; Mahipal A; McWilliams RR; Halfdanarson TR; Grothey AF
    Ann Surg; 2021 Feb; 273(2):341-349. PubMed ID: 30946090
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Laparoscopic Versus Open Distal Pancreatectomy for Pancreatic Adenocarcinoma.
    Stauffer JA; Coppola A; Mody K; Asbun HJ
    World J Surg; 2016 Jun; 40(6):1477-84. PubMed ID: 26847665
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma.
    Rowan DJ; Hartley CP; Aldakkak M; Christians KK; Evans DB; Tsai S; Hagen CE
    Ann Diagn Pathol; 2020 Jun; 46():151485. PubMed ID: 32172219
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Neoadjuvant chemotherapy is associated with improved survival in patients with left-sided pancreatic adenocarcinoma.
    Ocuin LM; Hardacre JM; Ammori JB; Rothermel LD; Mohamed A; Selfridge JE; Bajor D; Winter JM
    J Surg Oncol; 2020 Dec; 122(8):1595-1603. PubMed ID: 32844445
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
    Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pancreatic adenocarcinoma: effects of neoadjuvant therapy on post-pancreatectomy outcomes - an American College of Surgeons National Surgical Quality Improvement Program targeted variable review.
    Czosnyka NM; Borgert AJ; Smith TJ
    HPB (Oxford); 2017 Oct; 19(10):927-932. PubMed ID: 28747265
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.
    Yamada D; Eguchi H; Iwagami Y; Asaoka T; Noda T; Kawamoto K; Gotoh K; Kobayashi S; Mori M; Doki Y
    Surg Today; 2018 Oct; 48(10):952-962. PubMed ID: 29770847
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
    Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma.
    Li B; Shen S; You S; Zhang G; Gao S; Shi X; Wang H; Yin X; Xu X; Guo S; Jin G
    BMC Cancer; 2021 May; 21(1):612. PubMed ID: 34034684
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma.
    Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):109-120. PubMed ID: 33825991
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
    Kurreck A; Weckwerth J; Modest DP; Striefler JK; Bahra M; Bischoff S; Pelzer U; Oettle H; Kruger S; Riess H; Sinn M
    Eur J Cancer; 2021 Jun; 150():250-259. PubMed ID: 33940349
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluating the caregiver experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma.
    Ruff SM; Stevens L; Bressler L; Khatri R; Sarna A; Ejaz AM; Dillhoff M; Pawlik TM; Rose K; Cloyd JM
    J Surg Oncol; 2024 Mar; 129(4):775-784. PubMed ID: 38063046
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence.
    Müller PC; Frey MC; Ruzza CM; Nickel F; Jost C; Gwerder C; Hackert T; Z'graggen K; Kessler U
    Pharmacology; 2021; 106(3-4):143-153. PubMed ID: 32966993
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical impact of additional therapy for residual pancreatic cancer.
    Yamada S; Sonohara F; Tashiro M; Murotani K; Takami H; Hayashi M; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujii T; Kodera Y
    Surg Today; 2020 May; 50(5):440-448. PubMed ID: 31650262
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection.
    Boone BA; Zenati MS; Rieser C; Hamad A; Al-Abbas A; Zureikat AH; Hogg ME; Neal MD; Zeh HJ
    Ann Surg Oncol; 2019 May; 26(5):1503-1511. PubMed ID: 30652227
    [TBL] [Abstract][Full Text] [Related]  

  • 78. AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatment sequencing.
    Oppliger FA; Prakash LR; Newhook TE; Chiang YJ; Ikoma N; Maxwell JE; Kim MP; Vauthey JN; Lee JE; Katz MH; Tzeng CD
    Surg Oncol; 2022 Mar; 40():101673. PubMed ID: 34894620
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
    Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
    PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.